Modelling mode of trial

This paper presents a quantitative analysis of data collected from the mode of trial hearing in two English magistrates' courts. A model of the mode of trial procedure is offered that explores the factors that influence the mode of trial decision taken by magistrates. While legal factors such as seriousness of the offence play a part in the process, the mode of trial decision is also shaped by factors such as courtroom culture, the provision of bail and ethnicity. While this study is, in many respects, exploratory, it does point towards the importance of these extra legal factors in the mode of trial decision and indicate future areas for research

Pressure redistributing static chairs for preventing pressure ulcers (Protocol)

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effects of pressure redistributing static chairs on the prevention of pressure ulcers in health, rehabilitation, social care settings, and places of residence in which people may spend their day

The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy:Considerations for the design of clinical trials

Objective: With the emergence of experimental therapies for Duchenne muscular dystrophy (DMD), it is fundamental to understand the natural history of this disorder to properly design clinical trials. The aims of this study were to assess the effects produced on motor function by different DMD genotypes and early initiation of glucocorticoids. Methods: Through the NorthStar Network, standardised clinical data including the NorthStar Ambulatory Assessment score (NSAA) on 513 ambulant UK boys with DMD were analysed from 2004 to 2012. For the analysis of the genetic subpopulation, we also included data from 172 Italian boys with DMD. NSAA raw scores were converted into linear scores. Results: On the linearised NSAA, we observed an average decline of 8 units/year (4 units on raw NSAA analysis) after age 7. The median age at loss of ambulation (LOA) was 13 years (95% CI 12.1 to 13.5); 2 years prior to LOA, the estimated mean linearised NSAA score was 42/100 (13/34 raw scale). Starting glucocorticoids between 3 and 5 years conferred an additional gain in motor function of 3 units/year (1.3 raw units) up to age 7. When analysing the effect of genotype in the UK and Italian cumulative cohorts, individuals with deletions amenable to exons 44 and 46 skipping declined at a slower rate over 2 years (9 units (4 raw units), p<0.001), while 53 and 51 skippable deletions showed a faster decline of 14 (4.5; p<0.001) and 5 linearised units (2.4 NSAA units; p=0.02), respectively. Conclusions: Our study provides a novel insight on the current natural history of DMD, which will be instrumental for the design of future clinical trials